![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or...
Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision...
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million...
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or...
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded by 10.7 percentage...
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -2.48226950355 | 2.82 | 2.87 | 2.62 | 13693 | 2.73485924 | CS |
4 | 0.36 | 15.0627615063 | 2.39 | 2.98 | 2.25 | 25134 | 2.74331166 | CS |
12 | -0.35 | -11.2903225806 | 3.1 | 3.2 | 2.25 | 30761 | 2.81869946 | CS |
26 | -1.08 | -28.1984334204 | 3.83 | 4.44 | 2.21 | 53980 | 2.96415311 | CS |
52 | -0.79 | -22.3163841808 | 3.54 | 4.64 | 2.15 | 63031 | 3.15811072 | CS |
156 | -9.4 | -77.366255144 | 12.15 | 13.17 | 2.15 | 72567 | 4.24674637 | CS |
260 | -9.4 | -77.366255144 | 12.15 | 13.17 | 2.15 | 72567 | 4.24674637 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions